Advanced Oncotherapy PLC (AVO) Lowered to “Hold” at Beaufort Securities
Advanced Oncotherapy PLC (LON:AVO) traded up 0.48% during mid-day trading on Monday, reaching GBX 26.25. 425,605 shares of the company’s stock traded hands. Advanced Oncotherapy PLC has a 12-month low of GBX 23.88 and a 12-month high of GBX 209.88. The stock’s market capitalization is GBX 14.89 million. The stock has a 50-day moving average price of GBX 33.82 and a 200-day moving average price of GBX 67.12.
WARNING: “Advanced Oncotherapy PLC (AVO) Lowered to “Hold” at Beaufort Securities” was published by Marea Informative and is the sole property of of Marea Informative. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at http://www.mareainformativa.com/avanzado-oncoterapia-plc-avo-calificacion-de-acciones-bajado-de-beaufort-valores-2/109067/.
In other news, insider Enrico Cipro Vanni bought 25,000 shares of Advanced Oncotherapy PLC stock in a transaction that occurred on Tuesday, April 4th. The shares were purchased at an average price of GBX 29 ($0.37) per share, with a total value of £7,250 ($9,125.24). Also, insider Michael J. Sinclair bought 100,000 shares of Advanced Oncotherapy PLC stock in a transaction that occurred on Monday, April 3rd. The stock was purchased at an average cost of GBX 28 ($0.35) per share, for a total transaction of £28,000 ($35,242.29). Insiders have bought 225,000 shares of company stock worth $6,325,000 in the last three months.
About Advanced Oncotherapy PLC
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property.
Receive News & Stock Ratings for Advanced Oncotherapy PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy PLC and related stocks with our FREE daily email newsletter.